Venetoclax, a BCL-2 -selective inhibitor, has shown potent activity in inhibiting the growth of BCL-2-dependent hematological cancers but spares platelets, thus avoiding pronounced thrombocytopenia caused by BCL-XL inhibition (131). Here, BCL2 is linked to hematopoietic and lymphoid cell neoplasm.